Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **combination medical kit** containing three small-molecule components used together for office-based musculoskeletal or soft-tissue injection procedures: **lidocaine hydrochloride**, a local amide anesthetic that blocks voltage-gated sodium channels to provide rapid local anesthesia; **triamcinolone acetonide**, a synthetic glucocorticoid corticosteroid that activates the glucocorticoid receptor to suppress inflammatory signaling; and **povidone-iodine**, a topical iodophor antiseptic used to prepare the skin before injection. The kit has been marketed under multiple distributor-specific brand names for **joint, tunnel, and trigger-point injections**, typically supporting intra-articular or intramuscular administration workflows rather than representing a single co-formulated vial. Based on the provided context, it has been distributed by companies including Preferred Pharmaceuticals, SA3, and Asclemed USA, and FDA labeling indicates the kit labeling itself has not been approved by FDA and the product has not been found by FDA to be safe and effective.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine hydrochloride + triamcinolone acetonide + povidone-iodine.